StreetInsider.com News Articles

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2026 / New to The Street announces its upcoming Saturday broadcast airing across Bloomberg Television in the United States, Latin America, and the Middle East and North Africa (MENA), featuring innovative public companies, entrepreneurs, and industry thought leaders.

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

Medicus Pharma starts genomic endometriosis trial in UAE

Thu, 11 Jun 2026 07:30:23 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted an Investigational New Drug application to the Department of Health, Abu Dhabi for PRECISION-E2, a Phase 2a clinical trial evaluating Teverelix® in women with endometriosis in the United Arab Emirates.

The study will enroll approximately 84 participants across multiple UAE sites and evaluate three Teverelix treatment regimens using both subcutaneous and intramuscular administration. The trial aims to identify optimal dosing and administration methods for controlled estradiol suppression while maintaining safety.

PRECISION-E2 will leverage participants from the Emirati Genome Program to explore genetic variations that may influence treatment response. The study combines clinical outcomes, hormonal biomarkers, pharmacokinetic

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Thu, 11 Jun 2026 07:30:00 -0400

Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine therapy for women with endometriosis

PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi (DOH) for PRECISION-E2, a first-of-its-kind, Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Thu, 11 Jun 2026 07:30:00 -0400

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Thu, 11 Jun 2026 07:30:00 -0400

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Thu, 11 Jun 2026 07:30:00 -0400

Medicus Pharma submits European filing for Teverelix prostate cancer study

Mon, 08 Jun 2026 07:32:02 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted a substantial modification application through the European Union Clinical Trials Information System to support a planned Phase 2b study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk.

The submission supports the company's plan to initiate the Phase 2b study in 2026. The study targets prostate cancer patients requiring androgen deprivation therapy who have elevated cardiovascular risk, representing what the company estimates as a $4 billion annual market opportunity.

"Cardiovascular disease remains one of the most significant challenges facing men undergoing androgen deprivation therapy," stated Dr. Raza Bokhari, Medicus' Executive Chairman and CEO. "We

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Mon, 08 Jun 2026 07:30:00 -0400

European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity

PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS) supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer (APC).

The submission represents an important milestone in

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Mon, 08 Jun 2026 07:30:00 -0400

European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity

The submission represents an important milestone in

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Mon, 08 Jun 2026 07:30:00 -0400

European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity

The submission represents an important milestone in

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Mon, 08 Jun 2026 07:30:00 -0400

European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity

The submission represents an important milestone in

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

Featured Interviews Include Envoy Medical (NASDAQ:COCH), Big Sky Industrial (NASDAQ:BSIN), Graphene Manufacturing Group (OTCQX:GMGMF), Gold Royalty Corp. (NYSE American:GROY), and New York City's Acclaimed BlackBarn Restaurant

NEW YORK CITY, NY / ACCESS Newswire / June 6, 2026 / New to The Street, America's televised destination for discovering new investment ideas and "Opportunities To Consider™," announces tonight's nationally televised Bloomberg Television broadcast airing at 6:30 PM Eastern Time across the United States, Latin America, and the Middle East and North Africa (MENA) region.

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

Sat, 06 Jun 2026 11:20:00 -0400

This week's program features executive interviews and corporate updates from innovative